Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

NCT03245905 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

Interventions

DRUG: Chidamide

Sponsor

Sun Yat-sen University